Anabolic Therapeutics for Building New Bone

NEWS
OsteoGeneX News : :
Nov 2010
MidAmerica Healthcare - Detroit (MI). (Link)
Oct 2010
Springboard Enterprises Venture Forum - New York (NY). (Link)
Oct 2010
Life Sciences & Healthcare Venture Summit - Wall-Street (NY). (Link)
Sep 2010
Great Plains - Witchita (KS). (Link)
Jun 2010
BIO International Convention - Chicago (IL). (Link)
May 2010
C21 BioVentures - Napa (CA). (Link)
Aug 2008
KC Star - With Companies Such as OsteoGeneX, KC Aims to be a Backbone for Biotech . (Link)
Aug 2008 
Orthopedics This Week - OsteoGeneX Inc. Adds Board Members, Acquires $1.4 Million in Funding. (Link)
Aug 2008
Healthpoint Capital Orthopedic and Dental Industry News - Musculoskeletal News roundup. (Link)
June 2008
Kansas Biosciences Authority - Kansas invests millions to improve human health and launches three national bioscience programs. (Link)
June 2008
Ingram's Kansas City Business Magazine - Start It Up; Ingram's recognizes eight recent start-up businesses worth watching. (Link)
Aug 2007
Authority seeks partnerships. (Link)
July 2007
OsteoGeneX qualifies for Kansas State Angel Tax Credit.
Jul 2007
Startup keeps biotech local. (Link)
July 2007
OsteoGeneX awarded a Kansas Bioscience Authority Research Voucher. (Link 1, 2)
June 2007
OsteoGeneX showcased on Missouri Business Net. (Link)
May 2007
OsteoGeneX presents scientific results at BIO convention, Boston, MA. (Link)
April 2007
OsteoGeneX Showcased at the MedVestor Conference, Princeton, NJ.
Feb 2007
OsteoGeneX Awarded Missouri Senate Resolution by Senator Ridgeway. (Link)
Feb 2007
OsteoGeneX Showcased in Missouri Client Showcase, Jefferson City.
Oct 2006
OsteoGeneX featured as “Windhover -Selected Start-ups” In Vivo TOC - Windhover Health Care Business Intelligence. (Link)
Sep 2006
KTEC picks 10 for entrepreneur program. (Link)
July 2006
OsteoGeneX awarded Phase I SBIR grant from NIH NIAMS.
Q3 2006
Founding of OsteoGeneX Inc.
BACK TO TOP
 
History of Sclerostin (SOST) : :
2006
Sclerostin accepted to act on WNT pathway and regulate bone formation. Sclerostin and Wnt Signalling – the Pathway to Bone Strength. J Clinical Endocrinology & Metabolism 2005, 90(12) pg 6471. (Link)
2006
Seminal Publication by Ellies and Krumlauf showing Sclerostin does not bind to the Human High Bone Mass Mutated LRP5 Receptor. Journal Bone Mineral Research. November 2006:21:1738-1749 (doi: 10.1359/jbmr.060810). (Link)
Faculty of 1000 Medicine
“This article provides final evidence for the direct interaction between two of the (currently considered) most important targets in bone anabolism, Sclerostin and LRP5. Activating mutations in LRP5 and loss-of-function mutations in SOST encoding Sclerostin are both underlying sclerosing bone dysplasias with strong similarities, both clinically and radiologically.” ~ Wim van Hul (University of Antwerp, Belgium)

2005
Harvard Scientists publish Sclerostin as a ligand for Wnt co-receptor LRP5 and LRP6. (Link)
2002
Discovery of Sclerostin as Wnt Antagonist by Drs Ellies and Krumaluf at Stowers Institute. Wise/Sost nucleic acid sequences and amino acid sequences. Patent 20040023356. (Link)
2001
Sclerostin (SOST) positionally cloned by Celltech from an Afrikaner population presenting with 5X increase in bone density and hypothesized to function as a BMP antagonist. (Link)
Web Hosting Companies